 "Bharat Biotech's Bengaluru unit has overcome glitches, says V K Paul")
Bharat Biotech, the maker of the Covaxin vaccine, has overcome initial hiccups at its Bengaluru facility and is on track to go ahead as planned, said V K Paul, chairman of the national Covid task force, and member-health, NITI Aayog.
Paul said the company has added two facilities in Ankleshwar and Bengaluru as part of its expansion plans. While Ankleshwar has started production, according to schedule, there were some issues with initial stabilisation due to unforeseen circumstances.
“Production was a little behind expectations, but issues have been addressed. The production it had planned will be achieved,” said Paul.
Bharat Biotech is hoping to manufacture 1 billion doses per annum by the end of this year.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%